Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Nov, 2016 | Pages:
159 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Hemophilia A - Pipeline Review, H2 2016 Summary Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Hemophilia A - Pipeline Review, H2 2016, provides an overview of the Hemophilia A (Hematological Disorders) pipeline landscape. Hemophilia A is an X-linked, recessive disorder caused by deficiency of functional plasma clotting factor VIII (FVIII), which may be inherited or arise from spontaneous mutation. Depending on the level of FVIII activity, patients with hemophilia may present with easy bruising, inadequate clotting of traumatic injury or in the case of severe hemophilia spontaneous hemorrhage. Symptoms may include bleeding into joints, with associated pain and swelling, blood in the urine or stool, bruising, gastrointestinal tract and urinary tract hemorrhage, nosebleeds, prolonged bleeding from cuts, tooth extraction, and surgery and spontaneous bleeding. Report Highlights Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Hemophilia A - Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Hemophilia A (Hematological Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The Hemophilia A (Hematological Disorders) pipeline guide also reviews of key players involved in therapeutic development for Hemophilia A and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical, Discovery and Unknown stages are 5, 8, 4, 4, 21, 2 and 1 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.Hemophilia A. Hemophilia A (Hematological Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data. Scope - The pipeline guide provides a snapshot of the global therapeutic landscape of Hemophilia A (Hematological Disorders). - The pipeline guide reviews pipeline therapeutics for Hemophilia A (Hematological Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources. - The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. - The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities. - The pipeline guide reviews key companies involved in Hemophilia A (Hematological Disorders) therapeutics and enlists all their major and minor projects. - The pipeline guide evaluates Hemophilia A (Hematological Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type. - The pipeline guide encapsulates all the dormant and discontinued pipeline projects. - The pipeline guide reviews latest news related to pipeline therapeutics for Hemophilia A (Hematological Disorders) Reasons To Buy - Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. - Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage. - Find and recognize significant and varied types of therapeutics under development for Hemophilia A (Hematological Disorders). - Classify potential new clients or partners in the target demographic. - Develop tactical initiatives by understanding the focus areas of leading companies. - Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics. - Formulate corrective measures for pipeline projects by understanding Hemophilia A (Hematological Disorders) pipeline depth and focus of Indication therapeutics. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope. - Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2 List of Tables 5 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Hemophilia A Overview 8 Therapeutics Development 9 Pipeline Products for Hemophilia A - Overview 9 Pipeline Products for Hemophilia A - Comparative Analysis 10 Hemophilia A - Therapeutics under Development by Companies 11 Hemophilia A - Therapeutics under Investigation by Universities/Institutes 13 Hemophilia A - Pipeline Products Glance 14 Late Stage Products 14 Clinical Stage Products 15 Early Stage Products 16 Unknown Stage Products 17 Hemophilia A - Products under Development by Companies 18 Hemophilia A - Products under Investigation by Universities/Institutes 21 Hemophilia A - Companies Involved in Therapeutics Development 22 Alnylam Pharmaceuticals Inc 22 Amarna Therapeutics BV 23 Apitope International NV 24 Bayer AG 25 Biogen Inc 26 BioMarin Pharmaceutical Inc 27 Catalyst Biosciences Inc 28 Chugai Pharmaceutical Co Ltd 29 CSL Ltd 30 DBV Technologies SA 31 Dimension Therapeutics Inc 32 Emergent BioSolutions Inc 33 EpiVax Inc 34 Expression Therapeutics LLC 35 Green Cross Corp 36 Idogen AB 37 Lentigen Technology Inc 38 mAbxience SA 39 Novo Nordisk A/S 40 Octapharma AG 41 OPKO Biologics Ltd 42 Pfizer Inc 43 Pharming Group NV 44 rEVO Biologics Inc 45 Sangamo BioSciences Inc 46 Shire Plc 47 SK Chemicals Co Ltd 48 Spark Therapeutics Inc 49 UniQure NV 50 XL-protein GmbH 51 Hemophilia A - Therapeutics Assessment 52 Assessment by Monotherapy Products 52 Assessment by Target 53 Assessment by Mechanism of Action 55 Assessment by Route of Administration 57 Assessment by Molecule Type 59 Drug Profiles 61 antihemophilic factor - Drug Profile 61 antihemophilic factor (human) - Drug Profile 65 antihemophilic factor (recombinant) - Drug Profile 69 antihemophilic factor (recombinant) - Drug Profile 70 antihemophilic factor (recombinant) - Drug Profile 71 antihemophilic factor (recombinant) - Drug Profile 72 antihemophilic factor (recombinant) - Drug Profile 73 antihemophilic factor (recombinant) - Drug Profile 74 antihemophilic factor (recombinant) biosimilar - Drug Profile 75 antihemophilic factor (recombinant) biosimilar - Drug Profile 76 antihemophilic factor (recombinant), pegylated - Drug Profile 77 antihemophilic factor (recombinant), single chain - Drug Profile 79 ATXF-8117 - Drug Profile 82 BAX-888 - Drug Profile 83 BAY-1093884 - Drug Profile 84 BMN-270 - Drug Profile 85 Cell Therapy to Target Coagulation Factor VIII for Hemophilia A - Drug Profile 87 coagulation factor VIIa (recombinant) - Drug Profile 88 coagulation factor VIII (human) - Drug Profile 90 concizumab - Drug Profile 91 CSL-689 - Drug Profile 92 damoctocog alfa pegol - Drug Profile 94 Deimmunized FVIII - Drug Profile 96 DTX-201 - Drug Profile 97 emicizumab - Drug Profile 98 ET-3 - Drug Profile 101 fitusiran - Drug Profile 102 Gene Therapy for Hematological Disorders - Drug Profile 108 Gene Therapy for Hemophilia A - Drug Profile 109 Gene Therapy to Activate Factor VIII for Hemophilia A - Drug Profile 110 IN-3012 - Drug Profile 111 Kovaltry - Drug Profile 112 LG-889 - Drug Profile 114 LR-769 - Drug Profile 115 marzeptacog alfa - Drug Profile 117 MG-1113A - Drug Profile 119 MOD-5014 - Drug Profile 120 PBB-8-IN - Drug Profile 123 PF-06741086 - Drug Profile 124 Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile 125 Recombinant Factor VIII Replacement for Hemophilia A - Drug Profile 127 Recombinant Protein for Hemophilia A - Drug Profile 128 Recombinant Proteins for Hemophilia A - Drug Profile 129 SB-525 - Drug Profile 130 SB-FVIII - Drug Profile 131 SHP-656 - Drug Profile 133 SPK-8011 - Drug Profile 135 SVF-VIIa - Drug Profile 136 Hemophilia A - Dormant Projects 137 Hemophilia A - Discontinued Products 139 Hemophilia A - Product Development Milestones 140 Featured News & Press Releases 140 Appendix 154 Methodology 154 Coverage 154 Secondary Research 154 Primary Research 154 Expert Panel Validation 154 Contact Us 154 Disclaimer 155
List of Tables
Number of Products under Development for Hemophilia A, H2 2016 13 Number of Products under Development for Hemophilia A - Comparative Analysis, H2 2016 14 Number of Products under Development by Companies, H2 2016 15 Number of Products under Development by Companies, H2 2016 (Contd..1) 16 Number of Products under Investigation by Universities/Institutes, H2 2016 17 Comparative Analysis by Late Stage Development, H2 2016 18 Comparative Analysis by Clinical Stage Development, H2 2016 19 Comparative Analysis by Early Stage Development, H2 2016 20 Comparative Analysis by Unknown Stage Development, H2 2016 21 Products under Development by Companies, H2 2016 22 Products under Development by Companies, H2 2016 (Contd..1) 23 Products under Development by Companies, H2 2016 (Contd..2) 24 Products under Investigation by Universities/Institutes, H2 2016 25 Hemophilia A - Pipeline by Alnylam Pharmaceuticals Inc, H2 2016 26 Hemophilia A - Pipeline by Amarna Therapeutics BV, H2 2016 27 Hemophilia A - Pipeline by Apitope International NV, H2 2016 28 Hemophilia A - Pipeline by Bayer AG, H2 2016 29 Hemophilia A - Pipeline by Biogen Inc, H2 2016 30 Hemophilia A - Pipeline by BioMarin Pharmaceutical Inc, H2 2016 31 Hemophilia A - Pipeline by Catalyst Biosciences Inc, H2 2016 32 Hemophilia A - Pipeline by Chugai Pharmaceutical Co Ltd, H2 2016 33 Hemophilia A - Pipeline by CSL Ltd, H2 2016 34 Hemophilia A - Pipeline by DBV Technologies SA, H2 2016 35 Hemophilia A - Pipeline by Dimension Therapeutics Inc, H2 2016 36 Hemophilia A - Pipeline by Emergent BioSolutions Inc, H2 2016 37 Hemophilia A - Pipeline by EpiVax Inc, H2 2016 38 Hemophilia A - Pipeline by Expression Therapeutics LLC, H2 2016 39 Hemophilia A - Pipeline by Green Cross Corp, H2 2016 40 Hemophilia A - Pipeline by Idogen AB, H2 2016 41 Hemophilia A - Pipeline by Lentigen Technology Inc, H2 2016 42 Hemophilia A - Pipeline by mAbxience SA, H2 2016 43 Hemophilia A - Pipeline by Novo Nordisk A/S, H2 2016 44 Hemophilia A - Pipeline by Octapharma AG, H2 2016 45 Hemophilia A - Pipeline by OPKO Biologics Ltd, H2 2016 46 Hemophilia A - Pipeline by Pfizer Inc, H2 2016 47 Hemophilia A - Pipeline by Pharming Group NV, H2 2016 48 Hemophilia A - Pipeline by rEVO Biologics Inc, H2 2016 49 Hemophilia A - Pipeline by Sangamo BioSciences Inc, H2 2016 50 Hemophilia A - Pipeline by Shire Plc, H2 2016 51 Hemophilia A - Pipeline by SK Chemicals Co Ltd, H2 2016 52 Hemophilia A - Pipeline by Spark Therapeutics Inc, H2 2016 53 Hemophilia A - Pipeline by UniQure NV, H2 2016 54 Hemophilia A - Pipeline by XL-protein GmbH, H2 2016 55 Assessment by Monotherapy Products, H2 2016 56 Number of Products by Stage and Target, H2 2016 58 Number of Products by Stage and Mechanism of Actions H2 2016 60 Number of Products by Stage and Route of Administration, H2 2016 62 Number of Products by Stage and Molecule Type, H2 2016 64 Hemophilia A - Dormant Projects, H2 2016 141 Hemophilia A - Dormant Projects (Contd..1), H2 2016 142 Hemophilia A - Discontinued Products, H2 2016 143
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
